High dose cytarabine (HiDAC) is the most effective single agent studied to date for the treatment of acute myeloid leukemia (AML); clofarabine (CLOF) is also an active single agent in AML. Preclinical data suggest synergy between cytarabine and clofarabine. Based on the results of a limited phase 1 trial (
Disclosures: Powell:Genzyme Oncology: Research Funding. Off Label Use: Clofarabine is not approved for treatment of AML.